IntelliPharmaCeutics International Inc. Surges to 52-Week High, Is Now Top Performer

 IntelliPharmaCeutics International Inc. Surges to 52 Week High, Is Now Top Performer

The stock of IntelliPharmaCeutics International Inc. (TSE:I) hit a new 52-week high and has $4.67 target or 8.00% above today’s $4.32 share price. The 5 months bullish chart indicates low risk for the $128.08M company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $4.67 price target is reached, the company will be worth $10.25 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 16,562 shares traded hands. IntelliPharmaCeutics International Inc. (TSE:I) has risen 52.43% since April 21, 2016 and is uptrending. It has outperformed by 47.03% the S&P500.

More news for IntelliPharmaCeutics International Inc. (TSE:I) were recently published by: Quotes.Wsj.com, which released: “News Intellipharmaceutics International Inc.IPCI” on February 11, 2011. Seekingalpha.com‘s article titled: “IntelliPharmaCeutics International Has Huge Upside With Limited Downside” and published on November 10, 2016 is yet another important article.

IntelliPharmaCeutics International Inc is a Canada pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has a market cap of $128.08 million. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It currently has negative earnings. It has developed several drug delivery systems and a pipeline of products and product candidates in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

I.TO Company Profile

Intellipharmaceutics International Inc., incorporated on October 22, 2009, is a pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, the Company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment